Prescribers Portal

Medical Cannabis regulations are changing. From October 1st, Medleaf’s CBD100 product will cease distribution, although pharmacies with patients on repeat prescriptions will still be able to dispense post October 1st, until there own stocks are depleted.

Medleaf is committed to patient affordability, and has some cost leading commercial agreements. Ultimately, we are aiming for a Full spectrum CBD product to retail for 5c per mg of CBD, as opposed to out competitor retailing at over 10c per mg for an Isolate formulation.

Progress has been hamstrung by various aspects of the regulations, which exceed requirements elsewhere. Due to the lack of competition, it is highly likely that a third extension will be granted,

Australia for example, has over 190 products available, while the the regulations in NZ have delivered only 1 company that can meet the standards so far after over a year since the regime went live.

Retail costs are expected to work out to around $10 a day to patients using Oils, with the aim of undercutting our primary competitor Tilray, but 15% or more on a cost per mg of active ingredient for comparable products.

Our Flower product is expected to match illicit market pricing, providing a strong value proposition as a stronger, safer product for those who have become reliant on the rapid effects obtained via inhalation.

Follow the tabs to learn more about each future product.

Medleaf CBD 100 is a standardised dose solution of 100mg per ml of CBD in a Hemp Seed Oil Carrier. It is available until April 1st 2021

Medleaf CBD 100 is a broad-spectrum product derived from Hemp, and as such contains trace amounts of other Cannabinoids and Terpenes. As a broad-spectrum product it will have a stronger taste and smell than purified isolate products.

The product has been batch tested to ensure that it is safe to use. However the testing has been done prior to the new regulations coming into effect on April 1st 2020, and as such the existing stocks have not been tested against the full suite of pesticides the NZ regulations will require. You can see the Certificate of Analysis for the latest batch here

Medleaf Medium THC Flower, (full designation Medleaf Medium THC 15.5% Flower 30g “Shishkaberry”) is a premium flower product for patients who prefer inhalation methods, and is intended for daily use.

Availability is expected by June 2021, with pricing at low margin pharmacies expecting to reach under $15 a day for 1g daily consumption.

Manufactured by Canadian company Northern Green, the flower is unique by NZ standards with rare terpene Ocimene being very dominant, and flower being processed to high standards, remove stems and low potency leaves, leaving a desireable flower product for patients.

Dosing is best done with a Mighty Medic TM handheld vaporizer (pictured below), which comes with steel canisters that can be loaded with approx 0.2g of ground flower each, allowing for 5 doses a day as a Months supply.

Packaging render and sample COA above

Cannaqix 50 is discontinued in New Zealand.

While manufactured in a pharmaceutical GMP facility in Switzerland, other processing steps were performed in line with regulations for nutraceuticals.

It was uneconomical for Medleaf’s Partner Creso, to bring operations up to standard for a small market like New Zealand.

Medleaf is committed to offering excellence for patients, whether it be novel formats such as Cannaqix 50, or pricing.